DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update - Management to host business update conference call and webcast on Monday

Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

to host business update conference call and webcast on Monday, November 23, 2015 at 4:30 p.m. ET / 1:30 p.m. PT -

British Columbia and MENLO PARK, Calif., November 17, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar"

and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies,

today announced its financial results for the first quarter of the 2016 fiscal year ending September 30, 2015. The Company also

provided a recap of recent corporate and clinical program highlights and an overview of expected near-term milestones.

host a conference call and live webcast for investors, analysts and other interested parties on Monday, November 23rd at 4:30

p.m. ET / 1:30 p.m. PT. During the call, management will provide a business update and discuss DelMar's data presentation

at the Society for Neuro-Oncology ("SNO") Annual meeting, which will be held November 19-22, 2015, at the Marriott

Riverfront Hotel in San Antonio, Texas.

have made tremendous progress in executing our clinical development strategy with VAL-083 in refractory glioblastoma multiforme

("GBM") and identifying additional value drivers through non-clinical research that position us to expand our clinical

development efforts into non-small cell lung cancer ("NSCLC") and other solid tumors. We have completed full enrollment

of the Phase II expansion cohort in our refractory GBM clinical trial. The results of this study will be the basis for advancing

VAL-083 into the planned registration-directed Phase II/III trial in refractory GBM," stated Jeffrey Bacha, president and

CEO of DelMar Pharmaceuticals.

clinical development expansion strategy for VAL-083 is proceeding as planned, and we expect to initiate new clinical studies in

newly diagnosed GBM and NSCLC patients in the near future," added Mr. Bacha. "Our research collaborations continue

to explore the mechanism of VAL-083 and these efforts have unlocked further opportunities for VAL-083 to address unmet medical

needs by providing improved treatment options for patients with other tumor types, including ovarian cancer and difficult to treat

sub-types of malignant pediatric brain tumors."

CORPORATE HIGHLIGHTS

am extremely pleased with our significant achievements in recent months. DelMar is well positioned for major developments as VAL-083

advances toward registration-directed studies for refractory GBM and into clinical trials for new indications. We anticipate that

the VAL-083 program will continue to produce key data during the remainder of 2015 and throughout 2016," concluded Mr. Bacha.

NEAR-TERM MILESTONES

to host a conference call on Monday, November 23, 2015, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time, to discuss quarterly

results and the Company's presentation at the Society for Neuro-Oncology annual meeting. For both "listen-only"

participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is (844)

303-8663 (toll-free) with Conference ID 81768802. A link to the webcast and slides will be available on the IR Calendar of the

Investors section of the Company's website at www.delmarpharma.com, and will be archived for 30 days.

OF FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL YEAR 2016 ENDED SEPTEMBER 30, 2015

three months ended September 30, 2015 the Company reported a net loss of $1,621,388, or a net loss per share of $0.04, compared

to a net loss of $1,516,736, or a net loss per share of $0.04 for the three months ended September 30, 2014. In connection with

the preparation of the Company's financial statements for the three months ended September 30, 2015, and following discussion

with a third party accounting consultant, it was determined that the certain common stock purchase warrants issued by the Company

for placement agents' services on March 6, 2013 (the "Placement Agent Warrants") should have been originally

accounted for as a derivative liability in our audited financial statements. We determined that this was a material adjustment

and as a result we have restated our audited June 30, 2015 and 2014 annual financial statements to report the impacts of the accounting

error retroactive to March 2013.

strive to maintain the utmost integrity in all aspects of our business. Importantly, the reclassification of the Placement Agent

Warrants does not affect our working capital or our operations as we seek to build shareholder value by implementing DelMar's

business plan," stated Mr. Bacha. "The fundamentals of our business, including developing our portfolio of clinical

and non-clinical data supporting the potential of VAL-083 to address modern unmet medical needs in the treatment of cancer and

the solid experience base of our development team, remain strong."

three months ended September 30, 2015 the Company completed a public offering of its shares and warrants for gross proceeds of

management's current projections, the Company has enough capital to fund its operations into the third quarter of 2016.

represents selected financial information as of September 30, 2015. The Company's financial information has been prepared

in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar's consolidated financial

statements and Management's Discussion and Analysis ("MD&A"), as filed.

financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

is a "first-in-class," small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored

by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain,

cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments. VAL-083 is approved in

China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe

and the U.S. for the treatment of malignant gliomas.

demonstrated that VAL-083's anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated

in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar (temozolomide).

announced the completion of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM. Patients have been enrolled

at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated

with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO).

I dose-escalation portion of the study, VAL-083 was well tolerated at doses up to 40mg/m2 using a regimen of daily

x 3 every 21 days. Adverse events were typically mild to moderate; no treatment-related serious adverse events reported at doses

up to 40 mg/m2. Dose limiting toxicity (DLT) defined by thrombocytopenia (low platelet counts) was observed in two

of six (33%) of patients at 50 mg/m2. Generally, DLT-related symptoms resolved rapidly and spontaneously without concomitant

treatment, although one patient who presented with hemorrhoids received a platelet transfusion as a precautionary measure.

analysis of data from the Phase I dose-escalation portion of the study suggested a dose-dependent and clinically meaningful survival

benefit following treatment with VAL-083 in GBM patients whose tumors had progressed following standard treatment with temozolomide,

radiotherapy, bevacizumab and a range of salvage therapies.

in a low dose ( 5mg/m2) sub-group had a median survival of approximately five (5) months versus median survival

of approximately nine (9) months for patients in the therapeutic dose (30mg/m2 & 40mg/m2) sub-group

following initiation of VAL-083 treatment. DelMar reported increased survival at 6, 9 and 12 months following initiation of treatment

with VAL-083 in the therapeutic dose sub-group compared to the low dose sub-group.

details can be found at http://www.delmarpharma.com/scientific-publications.html.

DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals,

Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable

to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials

in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National

Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published

pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action

that could provide improved treatment options for patients.

information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com

/ (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. Investor Relations Counsel: Amato &

contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on

current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results

to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's

ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products

and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research

and development, clinical studies and future product commercialization; and, the Company's business, research, product development,

regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in

more detail in our filings with the SEC, including, our current reports on Form 8-K.